These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

192 related items for PubMed ID: 9179189

  • 1. Pulmonary metastases in metastatic prostate cancer: host tissue-tumor cell interactions and response to hormone therapy.
    Behrakis P, Koutsilieris M.
    Anticancer Res; 1997; 17(3A):1517-8. PubMed ID: 9179189
    [Abstract] [Full Text] [Related]

  • 2. [Solitary peritoneal carcinomatosis in prostate cancer].
    Brehmer B, Makris A, Wellmann A, Jakse G.
    Aktuelle Urol; 2007 Sep; 38(5):408-9. PubMed ID: 17907070
    [Abstract] [Full Text] [Related]

  • 3. Update on Memorial Sloan-Kettering Cancer Center studies of neoadjuvant hormonal therapy for prostate cancer.
    Fair WR, Betancourt JE.
    Mol Urol; 2000 Sep; 4(3):241-8;discussion 249-50. PubMed ID: 11062380
    [Abstract] [Full Text] [Related]

  • 4. Clinical significance of pulmonary metastases in stage D2 prostate cancer patients.
    Nakamachi H, Suzuki H, Akakura K, Imamoto T, Ueda T, Ishihara M, Furuya Y, Ichikawa T, Igarashi T, Ito H.
    Prostate Cancer Prostatic Dis; 2002 Sep; 5(2):159-63. PubMed ID: 12497007
    [Abstract] [Full Text] [Related]

  • 5. Neuroendocrine differentiation of localized prostate cancer during endocrine therapy.
    Nemoto K, Tomita Y.
    Scand J Urol Nephrol; 2007 Sep; 41(6):558-60. PubMed ID: 17853028
    [Abstract] [Full Text] [Related]

  • 6. Prognostic significance of tissue prostate-specific antigen in endocrine-treated prostate carcinomas.
    Stege R, Grande M, Carlström K, Tribukait B, Pousette A.
    Clin Cancer Res; 2000 Jan; 6(1):160-5. PubMed ID: 10656445
    [Abstract] [Full Text] [Related]

  • 7. Biochemical remission after resection of prostate cancer lung metastasis.
    Chao DH, Higgins JP, Brooks JD.
    Urology; 2004 Mar; 63(3):584-5. PubMed ID: 15028469
    [Abstract] [Full Text] [Related]

  • 8. Dramatic response of pulmonary metastasis from prostatic cancer to LH-RH agonist treatment.
    Heyman J, Leiter E.
    Mt Sinai J Med; 1989 Mar; 56(2):108-10. PubMed ID: 2501670
    [Abstract] [Full Text] [Related]

  • 9. Androgen level variations, clinical response to LHRH agonists and changes in the quality of life subscales in metastatic prostate cancer--speculations about possible role of the monoamine system.
    Popov I, Jelić S, Radosavljević D, Nikolić-Tomasević Z.
    Neoplasma; 1997 Mar; 44(5):308-13. PubMed ID: 9473791
    [Abstract] [Full Text] [Related]

  • 10. Prostate-specific antigen half-life and pretreatment prostate-specific antigen: crucial predictors for prostate-specific antigen trend in delayed-combined androgen blockade therapy.
    Soga N, Onishi T, Arima K, Sugimura Y.
    Int J Urol; 2007 Mar; 14(3):192-6; discussion 197. PubMed ID: 17430253
    [Abstract] [Full Text] [Related]

  • 11. [Giant prostate carcinoma treated effectively with endocrine therapy: case report].
    Masue N, Hasegawa Y.
    Hinyokika Kiyo; 2007 Feb; 53(2):133-5. PubMed ID: 17352166
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Undetectable prostate specific antigen at 6-12 months: a new marker for early success in hormonally treated patients after prostate brachytherapy.
    Miller N, Smolkin ME, Bissonette E, Theodorescu D.
    Cancer; 2005 Jun 15; 103(12):2499-506. PubMed ID: 15852361
    [Abstract] [Full Text] [Related]

  • 14. Serum testosterone recovery after cessation of long-term luteinizing hormone-releasing hormone agonist in patients with prostate cancer.
    Bong GW, Clarke HS, Hancock WC, Keane TE.
    Urology; 2008 Jun 15; 71(6):1177-80. PubMed ID: 18279929
    [Abstract] [Full Text] [Related]

  • 15. Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trial.
    James ND, Caty A, Borre M, Zonnenberg BA, Beuzeboc P, Morris T, Phung D, Dawson NA.
    Eur Urol; 2009 May 15; 55(5):1112-23. PubMed ID: 19042080
    [Abstract] [Full Text] [Related]

  • 16. PSA bouncing after short term androgen deprivation and 3D-conformal radiotherapy for localized prostate adenocarcinoma and the relationship with the kinetics of testosterone.
    Akyol F, Ozyigit G, Selek U, Karabulut E.
    Eur Urol; 2005 Jul 15; 48(1):40-5. PubMed ID: 15967250
    [Abstract] [Full Text] [Related]

  • 17. Equivalent and sufficient effects of leuprolide acetate and goserelin acetate to suppress serum testosterone levels in patients with prostate cancer.
    Fujii Y, Yonese J, Kawakami S, Yamamoto S, Okubo Y, Fukui I.
    BJU Int; 2008 May 15; 101(9):1096-100. PubMed ID: 18190637
    [Abstract] [Full Text] [Related]

  • 18. Prostate-cancer-specific survival and clinical progression-free survival in men with prostate cancer treated intermittently with testosterone-inactivating pharmaceuticals.
    Scholz M, Lam R, Strum S, Jennrich R, Johnson H, Trilling T.
    Urology; 2007 Sep 15; 70(3):506-10. PubMed ID: 17905106
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.